Adicet Bio Net Worth
Adicet Bio Net Worth Breakdown | ACET |
Adicet Bio Net Worth Analysis
Adicet Bio's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Adicet Bio's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Adicet Bio's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Adicet Bio's net worth analysis. One common approach is to calculate Adicet Bio's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Adicet Bio's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Adicet Bio's net worth. This approach calculates the present value of Adicet Bio's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Adicet Bio's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Adicet Bio's net worth. This involves comparing Adicet Bio's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Adicet Bio's net worth relative to its peers.
Enterprise Value |
|
To determine if Adicet Bio is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Adicet Bio's net worth research are outlined below:
| Adicet Bio had very high historical volatility over the last 90 days | |
| Adicet Bio has some characteristics of a very speculative penny stock | |
| Adicet Bio has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (117.12 M) with profit before overhead, payroll, taxes, and interest of 24.99 M. | |
| Adicet Bio currently holds about 260.64 M in cash with (92.38 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.11, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Adicet Bio has a poor financial position based on the latest SEC disclosures | |
| Roughly 64.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: MaxCyte Expands Cell Therapy Reach Strategic License Deal Powers Adicets Cancer Treatment Innovation - Stock Titan |
Adicet Bio uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Adicet Bio. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Adicet Bio's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 20th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Adicet Bio's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Adicet Bio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Adicet Bio backward and forwards among themselves. Adicet Bio's institutional investor refers to the entity that pools money to purchase Adicet Bio's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Regeneron Pharmaceuticals Inc | 2025-03-31 | 968.2 K | Bridgeway Capital Management, Llc | 2025-03-31 | 901.6 K | Renaissance Technologies Corp | 2025-03-31 | 810.7 K | Geode Capital Management, Llc | 2025-03-31 | 770.7 K | Blackrock Inc | 2025-03-31 | 749.1 K | Alyeska Investment Group, L.p. | 2025-03-31 | 655.7 K | Two Sigma Advisers, Llc | 2025-03-31 | 622.8 K | Rbf Llc | 2025-03-31 | 617.3 K | Dafna Capital Management Llc | 2025-03-31 | 600 K | Orbimed Advisors, Llc | 2025-03-31 | 11.4 M | Tang Capital Management Llc | 2025-03-31 | 8.2 M |
Follow Adicet Bio's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 57.97 M.Market Cap |
|
Project Adicet Bio's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.53) | (0.51) | |
| Return On Capital Employed | (0.64) | (0.60) | |
| Return On Assets | (0.53) | (0.51) | |
| Return On Equity | (0.63) | (0.60) |
When accessing Adicet Bio's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Adicet Bio's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Adicet Bio's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Adicet Bio's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Adicet Bio. Check Adicet Bio's Beneish M Score to see the likelihood of Adicet Bio's management manipulating its earnings.
Evaluate Adicet Bio's management efficiency
Adicet Bio has return on total asset (ROA) of (0.3268) % which means that it has lost $0.3268 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5583) %, meaning that it created substantial loss on money invested by shareholders. Adicet Bio's management efficiency ratios could be used to measure how well Adicet Bio manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -0.51 in 2025. Return On Capital Employed is likely to gain to -0.6 in 2025. Total Current Liabilities is likely to drop to about 18.4 M in 2025. Liabilities And Stockholders Equity is likely to drop to about 165.8 M in 2025| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.12 | 2.02 | |
| Tangible Book Value Per Share | 2.12 | 3.71 | |
| Enterprise Value Over EBITDA | (0.41) | (0.43) | |
| Price Book Value Ratio | 0.45 | 0.43 | |
| Enterprise Value Multiple | (0.41) | (0.43) | |
| Price Fair Value | 0.45 | 0.43 | |
| Enterprise Value | 45.3 M | 43 M |
Adicet Bio benefits from a proactive management team that anticipates market trends. Our analysis delves into how this proactive stance influences financial metrics and stock valuation.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Adicet Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Adicet Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Adicet Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Adicet Bio time-series forecasting models is one of many Adicet Bio's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Adicet Bio's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Adicet Bio Earnings per Share Projection vs Actual
Adicet Bio Corporate Management
| Francesco MD | Chief VP | Profile | |
| BA CPA | Pres CEO | Profile | |
| Blake Aftab | Senior Officer | Profile | |
| Donald Healey | Chief Officer | Profile | |
| Amy Locke | Head Resources | Profile | |
| Brian Harvey | Chief Officer | Profile | |
| Julie MD | Chief Officer | Profile |
Already Invested in Adicet Bio?
The danger of trading Adicet Bio is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Adicet Bio is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Adicet Bio. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Adicet Bio is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Adicet Stock Analysis
When running Adicet Bio's price analysis, check to measure Adicet Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adicet Bio is operating at the current time. Most of Adicet Bio's value examination focuses on studying past and present price action to predict the probability of Adicet Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adicet Bio's price. Additionally, you may evaluate how the addition of Adicet Bio to your portfolios can decrease your overall portfolio volatility.